Nothing Special   »   [go: up one dir, main page]

DK0786998T3 - Anvendelse af [R-(Z)]-alfa-(metoxyimino)-alfa-(1-azabicyclo[2.2.2]oct-3-yl)acetonitril til reduktion af amyloid-beta-A4-dannelse ved Alzheimer's sygdom - Google Patents

Anvendelse af [R-(Z)]-alfa-(metoxyimino)-alfa-(1-azabicyclo[2.2.2]oct-3-yl)acetonitril til reduktion af amyloid-beta-A4-dannelse ved Alzheimer's sygdom

Info

Publication number
DK0786998T3
DK0786998T3 DK95936515T DK95936515T DK0786998T3 DK 0786998 T3 DK0786998 T3 DK 0786998T3 DK 95936515 T DK95936515 T DK 95936515T DK 95936515 T DK95936515 T DK 95936515T DK 0786998 T3 DK0786998 T3 DK 0786998T3
Authority
DK
Denmark
Prior art keywords
alpha
alzheimer
disease
pct
acetonitrile
Prior art date
Application number
DK95936515T
Other languages
English (en)
Inventor
Roger E Markwell
Julie Hawkins
Carol W Gray
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DK0786998T3 publication Critical patent/DK0786998T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK95936515T 1994-10-25 1995-10-17 Anvendelse af [R-(Z)]-alfa-(metoxyimino)-alfa-(1-azabicyclo[2.2.2]oct-3-yl)acetonitril til reduktion af amyloid-beta-A4-dannelse ved Alzheimer's sygdom DK0786998T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421472A GB9421472D0 (en) 1994-10-25 1994-10-25 Novel methods
PCT/EP1995/004082 WO1996012486A1 (en) 1994-10-25 1995-10-17 Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease

Publications (1)

Publication Number Publication Date
DK0786998T3 true DK0786998T3 (da) 2002-07-15

Family

ID=10763350

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95936515T DK0786998T3 (da) 1994-10-25 1995-10-17 Anvendelse af [R-(Z)]-alfa-(metoxyimino)-alfa-(1-azabicyclo[2.2.2]oct-3-yl)acetonitril til reduktion af amyloid-beta-A4-dannelse ved Alzheimer's sygdom

Country Status (22)

Country Link
US (1) US5891887A (da)
EP (1) EP0786998B1 (da)
JP (1) JPH10509697A (da)
KR (1) KR100393365B1 (da)
CN (1) CN1085529C (da)
AT (1) ATE214926T1 (da)
AU (1) AU698695B2 (da)
BG (1) BG101500A (da)
BR (1) BR9509433A (da)
CZ (1) CZ287370B6 (da)
DE (1) DE69526102T2 (da)
DK (1) DK0786998T3 (da)
ES (1) ES2173977T3 (da)
GB (1) GB9421472D0 (da)
HK (1) HK1002057A1 (da)
HU (1) HUT77007A (da)
NO (1) NO312055B1 (da)
NZ (1) NZ295155A (da)
PT (1) PT786998E (da)
SK (1) SK50497A3 (da)
WO (1) WO1996012486A1 (da)
ZA (1) ZA958946B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
EP1061918A1 (en) 1998-03-11 2000-12-27 Smithkline Beecham Plc Controlled release composition of (1-azabicyclo(2.2.2)oct-3-yl)acetonitrile monohydrochloride
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392803T3 (da) * 1989-04-13 2004-10-18 Beecham Group Plc Hidtil ukendte forbindelser
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
DE69526102T2 (de) 2002-10-31
BR9509433A (pt) 1997-09-16
AU698695B2 (en) 1998-11-05
SK50497A3 (en) 1997-09-10
BG101500A (en) 1998-01-30
EP0786998A1 (en) 1997-08-06
DE69526102D1 (de) 2002-05-02
KR100393365B1 (ko) 2003-12-18
ATE214926T1 (de) 2002-04-15
JPH10509697A (ja) 1998-09-22
WO1996012486A1 (en) 1996-05-02
CN1170365A (zh) 1998-01-14
NO312055B1 (no) 2002-03-11
HK1002057A1 (en) 1998-07-31
NO971899L (no) 1997-04-24
PT786998E (pt) 2002-09-30
CZ287370B6 (en) 2000-11-15
ES2173977T3 (es) 2002-11-01
GB9421472D0 (en) 1994-12-07
NZ295155A (en) 2000-07-28
EP0786998B1 (en) 2002-03-27
KR970706816A (ko) 1997-12-01
CZ125197A3 (en) 1997-07-16
ZA958946B (en) 1996-08-20
AU3843195A (en) 1996-05-15
MX9703077A (es) 1997-07-31
NO971899D0 (no) 1997-04-24
US5891887A (en) 1999-04-06
CN1085529C (zh) 2002-05-29
HUT77007A (hu) 1998-03-02

Similar Documents

Publication Publication Date Title
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
TWI263503B (en) Composition comprising an antibody or a polypeptide preparation as the active agent for the prevention and treatment of amyloidogenic disease and method for in vitro screening of the antibody
EA200700232A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
TW200505900A (en) Muscarinic agonists
BR0315283A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de doenças neurológicas ou de doenças inflamatórias do trato respiratório superior
MY135838A (en) Methods for the treatment of mental disorders
GB2285219A (en) Use of norastemizole for the treatment of allergic disorders
DK0786998T3 (da) Anvendelse af [R-(Z)]-alfa-(metoxyimino)-alfa-(1-azabicyclo[2.2.2]oct-3-yl)acetonitril til reduktion af amyloid-beta-A4-dannelse ved Alzheimer's sygdom
HUP9904401A2 (hu) [R-(Z)]-alfa-(Metoxi-imino)-alfa-(1-aza-biciklo[2.2.2]okt-3-il)-acetonitril-monohidroklorid hatóanyag-tartalmú szabályozott kibocsátású dózisforma
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
HUP0103149A2 (hu) Gyógyszerkészítmény Alzheimer-kór kezelésére
DK0642338T3 (da) Anvendelse af (E)-2-(p-fluorphenethyl)-3-fluorallylamin i behandlingen af Alzheimers sygdom
BR9913242A (pt) Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono
YU9302A (sh) Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa
DE60123136D1 (de) Methoden zur kolikenbehandlung